Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

People over profit: Pfizer and Moderna must share vaccine technology

Amber Gipson-Fine, MPH
Meds
March 3, 2022
1 Shares
Share
Tweet
Share

One year ago, the FDA granted emergency use authorization of mRNA COVID-19 vaccines in the U.S., and nearly 549 million total vaccine doses have been given since. These vaccines have been safe, effective methods in preventing infection and death from COVID-19.

Vaccine recipients had a lower overall risk of death from non-COVID-19 disease compared to unvaccinated counterparts.

Among available vaccines, mRNA products have been the most effective against COVID-19 and its variants. The benefits of vaccination, especially with mRNA technology, should not be limited to wealthy countries. With over 5.86 million COVID-19 deaths globally, less-vaccinated countries cannot wait to gain sufficient vaccine availability. They should also not have to wait for donated support. It is vital to share vaccine technology with the world to save more lives, not just the lives of Americans.

Moderna, the much younger company of the two mRNA vaccine producers, had a major stock crash this month as insiders cashed out on pandemic profits amid vaccine sale declines and subsiding Omicron cases. While Pfizer has experienced stock declines, albeit less steep, both companies’ trailing gross profits remain between $10 million for Moderna and $50 million for Pfizer.

A central contention to Pfizer and Moderna sharing mRNA technology is that other countries do not have the resources to follow the advanced, lengthy protocol to produce the vaccine. This, however, is not proven.

Doctors without Borders, with the help of AccessIBSA, has identified over 100 manufacturers in Asia, South America and Africa that have the baseline needs to produce an mRNA vaccine.

On the moral front, this is not the first time in history where a U.S.-based pharmaceutical company was called to action to place people over profit.

While in graduate school for public health, I analyzed a case study with my peers. A major American pharmaceutical company, Merck, could cure river blindness in several countries, but the drug would not garner profits. Onchocerciasis, or river blindness, is a parasitic disease that was causing agricultural communities to become blind and devastating people’s ability to care and provide for their families.

Painfully aware of the systems of capitalistic health care in the U.S., most of my classmates suspected the company would minimally intervene, if at all. Thankfully, that was incorrect.

In 1987, Merck pledged to donate Mectizan, a drug that cures river blindness, for as long as it was needed until the disease was no longer a threat to over 300 million people in 49 countries. The program is over 30 years old and remains as an ongoing triumph of pharmaceutical leadership.

Some may be quick to cite that the U.S. has donated over 140 million vaccine doses to other countries, with at least 1.1 billion doses pledged by 2023 during the Global Summit to End COVID-19.

Many of these vaccines are from Pfizer and Moderna, however, they were not free. The U.S. had to purchase vaccines from each company to then donate to the global campaign. While exact amounts were not disclosed, the original agreement with Pfizer in June of 2020 was $1.95 billion for 100 million vaccines, or $19.50 per dose. Countries with low vaccine availability, therefore, are largely at the discretion of vaccine production and shipping times from only the facilities that currently operate.

Financially, Moderna had a $3.3 billion net income in November 2021, which added 3 executives to Forbes’ 400 richest Americans list. It employs over 1,800 people with a net worth of $59 billion. Pfizer had $83.1 billion as total 2021 revenue, employs over 10,000 people, and has a net worth of $272 billion.

Stocks for both companies are currently experiencing market falls, but each can afford to share the life-saving technology and the subsequent trade agreements that would likely be enforced. Both companies received billions in government and private funding for the development and distribution of COVID-19 vaccines, excluding additional profits from other COVID-19-related products.

While the U.S. has over 64% of its total population fully vaccinated, and over 75% of its population has at least one dose of an EUA-approved vaccine, the 50 least wealthy countries have access to only 6.3% of total available vaccine products.

If multiple countries have the capacity to produce vaccines within their own borders, time is wasted waiting for Pfizer and Moderna to produce enough vaccines to reach all corners of the world.

The World Health Organization launched a vaccine equity campaign in the winter of 2021, underscoring the immediate need to better distribute COVID-19 vaccinations globally. The pandemic will not end without sufficient global vaccination.

Pfizer has a particular onus to help intervene globally as one of the largest and most profitable pharmaceutical companies in the world. With its immense capital power, Pfizer should shift some of their spending from national ads promoting their vaccine product in a country that has large booster vaccine availability to sharing the technology that can help countries self-produce and vaccinate their citizens much faster.

Even if new production facilities had delays from receiving the mRNA technology protocol to production, the months spent toward self-producing could be expediting vaccine receipt for countries otherwise waiting until the end of 2022 for donated vaccines.

In a pandemic that is approaching six million global deaths, time is the most valuable resource in fulfilling vaccine equity. Countries cannot wait to save lives while wealthy pharmaceutical companies gatekeep vital technology.

Amber Gipson-Fine is a project manager.

Image credit: Shutterstock.com

Prev

Why selling will make you a happier doctor

March 3, 2022 Kevin 1
…
Next

Don't forget the socks and shoes: a reflection on the third year of medical school

March 3, 2022 Kevin 0
…

Tagged as: COVID, Infectious Disease

Post navigation

< Previous Post
Why selling will make you a happier doctor
Next Post >
Don't forget the socks and shoes: a reflection on the third year of medical school

More by Amber Gipson-Fine, MPH

  • Why an apology matters in medicine

    Amber Gipson-Fine, MPH

Related Posts

  • Advocating for people with disabilities: People First Language

    Leonard Wang
  • The basics of the MMR vaccine from a pediatrician

    Roy Benaroch, MD
  • No, the HPV vaccine isn’t optional

    Chad Hayes, MD
  • A view from Canada: Defending vaccine passports

    Bryan Thomas and Colleen M. Flood
  • Major medical groups back mandatory COVID vaccine for health care workers

    Molly Walker
  • Novavax may be able to provide equitable access to another vaccine alternative

    Vibhav Prabhakar, Tejas Sekhar, and Divya Srinivasan

More in Meds

  • The deadly consequences of a shortage: The Pluvicto crisis leaves metastatic prostate cancer patients in limbo

    Matt Drewes
  • The real story of Xylazine contamination in street fentanyl and how we can manage it

    Julie Craig, MD
  • The cannabis education gap: Why patients are left in the dark

    Timothy Byars
  • Are doctors ready to discuss psychedelic therapies with patients?

    Thaís Salles Araujo, MD
  • The rise and dark side of fungi: Exploring health benefits and pathogenic threats

    Sandra Vamos, EdD and Deanna Lernihan, MPH
  • Advocacy and collaboration lead to major patient safety benefits on sterile pharmaceutical compounding: a review of USP’s revisions to Chapter <797>

    Elizabeth Rebello, MD
  • Most Popular

  • Past Week

    • Physician entrepreneurs offer hope for burned out doctors

      Cindy Rubin, MD | Physician
    • Boxing legends Tyson and Foreman: powerful lessons for a resilient and evolving health care future

      Harvey Castro, MD, MBA | Physician
    • Is chaos in health care leading us towards socialized medicine? How physician burnout is a catalyst.

      Howard Smith, MD | Physician
    • We need a new Hippocratic Oath that puts patient autonomy first

      Jeffrey A. Singer, MD | Physician
    • Unveiling the intricate link between housing costs and health care

      Harvey Castro, MD, MBA | Policy
    • Fixing the system and prioritizing patient care [PODCAST]

      The Podcast by KevinMD | Podcast
  • Past 6 Months

    • It’s time to replace the 0 to 10 pain intensity scale with a better measure

      Mark Sullivan, MD and Jane Ballantyne, MD | Conditions
    • “Is your surgeon really skilled? The hidden threat to public safety in medicine.

      Gene Uzawa Dorio, MD | Physician
    • Breaking the cycle of racism in health care: a call for anti-racist action

      Tomi Mitchell, MD | Policy
    • Revolutionize your practice: the value-based care model that reduces physician burnout

      Chandravadan Patel, MD | Physician
    • Unveiling the hidden damage: the secretive world of medical boards

      Alan Lindemann, MD | Physician
    • An inspiring tribute to an exceptional radiologist who made a lasting impact

      Kim Downey, PT | Conditions
  • Recent Posts

    • Fixing the system and prioritizing patient care [PODCAST]

      The Podcast by KevinMD | Podcast
    • From medical student to intern: Discovering a deeper connection with patients

      Johnathan Yao, MD, MPH | Physician
    • A physician’s typical day, as envisioned by a non-clinician health care MBA: a satire

      Jennifer Lycette, MD | Physician
    • Unveiling the global pandemic threat: insights into risk factors and urgent measures for prevention

      Ton La, Jr., MD, JD | Policy
    • Decoding name displays in health care: Privacy, identification, and compliance unveiled

      Deepak Gupta, MD | Physician
    • Empowering Black nurses for lasting change [PODCAST]

      The Podcast by KevinMD | Podcast

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

View 1 Comments >

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

CME Spotlights

From MedPage Today

Latest News

  • Novel IDH1/2 Inhibitor Shows 'Dramatic Effect' in Low-Grade Glioma
  • Nivolumab-AVD Boosts PFS in Untreated Hodgkin Lymphoma
  • 'You Can't Yoga Your Way Out of This': What We Heard This Week
  • New Standard in Operable EGFR-Positive Lung Cancer
  • New Ovarian Cancer Drug Extends Survival in Resistant Disease

Meeting Coverage

  • Novel IDH1/2 Inhibitor Shows 'Dramatic Effect' in Low-Grade Glioma
  • Nivolumab-AVD Boosts PFS in Untreated Hodgkin Lymphoma
  • New Standard in Operable EGFR-Positive Lung Cancer
  • New Ovarian Cancer Drug Extends Survival in Resistant Disease
  • Neoadjuvant Chemo Flops Versus Upfront Surgery for Resectable Pancreatic Cancer
  • Most Popular

  • Past Week

    • Physician entrepreneurs offer hope for burned out doctors

      Cindy Rubin, MD | Physician
    • Boxing legends Tyson and Foreman: powerful lessons for a resilient and evolving health care future

      Harvey Castro, MD, MBA | Physician
    • Is chaos in health care leading us towards socialized medicine? How physician burnout is a catalyst.

      Howard Smith, MD | Physician
    • We need a new Hippocratic Oath that puts patient autonomy first

      Jeffrey A. Singer, MD | Physician
    • Unveiling the intricate link between housing costs and health care

      Harvey Castro, MD, MBA | Policy
    • Fixing the system and prioritizing patient care [PODCAST]

      The Podcast by KevinMD | Podcast
  • Past 6 Months

    • It’s time to replace the 0 to 10 pain intensity scale with a better measure

      Mark Sullivan, MD and Jane Ballantyne, MD | Conditions
    • “Is your surgeon really skilled? The hidden threat to public safety in medicine.

      Gene Uzawa Dorio, MD | Physician
    • Breaking the cycle of racism in health care: a call for anti-racist action

      Tomi Mitchell, MD | Policy
    • Revolutionize your practice: the value-based care model that reduces physician burnout

      Chandravadan Patel, MD | Physician
    • Unveiling the hidden damage: the secretive world of medical boards

      Alan Lindemann, MD | Physician
    • An inspiring tribute to an exceptional radiologist who made a lasting impact

      Kim Downey, PT | Conditions
  • Recent Posts

    • Fixing the system and prioritizing patient care [PODCAST]

      The Podcast by KevinMD | Podcast
    • From medical student to intern: Discovering a deeper connection with patients

      Johnathan Yao, MD, MPH | Physician
    • A physician’s typical day, as envisioned by a non-clinician health care MBA: a satire

      Jennifer Lycette, MD | Physician
    • Unveiling the global pandemic threat: insights into risk factors and urgent measures for prevention

      Ton La, Jr., MD, JD | Policy
    • Decoding name displays in health care: Privacy, identification, and compliance unveiled

      Deepak Gupta, MD | Physician
    • Empowering Black nurses for lasting change [PODCAST]

      The Podcast by KevinMD | Podcast

MedPage Today Professional

An Everyday Health Property Medpage Today
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

People over profit: Pfizer and Moderna must share vaccine technology
1 comments

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...